Accelerated hypofractionated radiotherapy with concomitant chemotherapy in locally advanced squamous cell carcinoma of lung: evaluation of response, survival, toxicity and quality of life from a Phase II randomized study

Abstract

Cite this article as: Roy S, Pathy S, Mohanti BK, Raina V, Jaiswal A, Kumar R, et al. Accelerated hypofractionated radiotherapy with concomitant chemotherapy in locally advanced squamous cell carcinoma of lung: evaluation of response, survival, toxicity and quality of life from a Phase II randomized study. Conclusion:The study suggests that AHFx-RT-CT is feasible for locally advanced SCC of the lung with improved response rate, survival, QOL and favourable toxicity. Advances in knowledge: To the best of our knowledge, this is the first study comparing conventionally fractionated radiation with AHFx-RT-CT. Addition of low-dose weekly cisplatin as radiosensitizer may be the potential factor responsible for improved response rate, survival and favourable toxicity in the study arm despite lower biological effective dose.

Sequential or concomitant chemotherapy with hypofractionated radiotherapy for locally advanced non-small cell lung cancer: a meta-analysis of randomized trials

“…Recently, several phase I and II clinical trials have been designed to combine chemotherapy with hypofractionated radiotherapy (HYPO-RT) to intensify radiotherapy in a different way (13)(14)(15). These studies have demonstrated that irradiation delivered within a short period (4 or 5 weeks) and at a radiation dose of ≥2.5 Gy per fraction combined with chemotherapy is feasible and shows encouraging outcomes (13)(14)(15). The rationale supporting CRT with HYPO-RT is to limit tumor repopulation and enhance local control with consequent survival improvement (16,17).…”